Non Hodgkin Lymphoma Clinical Trial
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin’s Lymphoma (B-NHL)
The purpose of this study is to assess the safety and efficacy of IMM0306-02 in patients with refractory or relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL).
18-75 years old
Diagnosed with B-NHL
Relapsed after or be refractory to at least 2 line of standard therapy
Active central nervous system (CNS) metastases
Positive Direct Antiglobulin Test (DAT)
Active autoimmune disorder
Skin disorders that do not requires hormone replacement therapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Cincinnati Ohio, 45219, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.